MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Positive|Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7
Interventions: DRUG: Akt Inhibitor MK2206|DRUG: Anastrozole|DRUG: Fulvestrant|OTHER: Laboratory Biomarker Analysis
Sponsor: National Cancer Institute (NCI)